Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Wallace Peterson (NPI 1760472039)

Field	Value
Entity Type	Individual
Organization	Wallace Peterson
Address	4101 Tiger Lily Rd Ste 100
City	Lincoln
State	NE
ZIP	68516
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	October 26, 2005

Payer Source	Total Paid
Medicare	$1.5M
Medicaid	$0

Key Findings

This profile reads like an outpatient hematology/oncology infusion practice: the top revenue drivers are oncology biologics and related administration codes, and the CPT/HCPCS mix includes high-revenue immunotherapies and multiple chemotherapy administration codes. The three dominant drug codes — J9299 $438.7K (30.5%), J9271 $404.2K (28.1%), and J0897 $181.4K (12.6%) — plus chemotherapy administration codes such as 96413 and infusion add‑ons indicate routine in‑office infusion of high-cost oncology agents and supportive treatments.

Revenue is highly concentrated: the precomputed top‑3 codes account for 71.3% of this provider's total Medicare revenue, and total Medicare revenue on file is $1.5M. That concentration means a small number of high‑cost drugs (listed above) drive the majority of billed Medicare dollars for this provider.

This provider is effectively single‑payer in the dataset: Medicare revenue is $1.5M and there is no Medicaid billing on file. The absence of Medicaid activity means payer mix is heavily skewed to Medicare, which reduces diversification and makes the practice more sensitive to Medicare reimbursement changes for the specific high‑value oncology drugs it bills.

Competitive standing across top drugs is mixed rather than dominant. For J9299 the provider ranks #192 of 505 (62th percentile; typical, unremarkable volume), for J9271 the provider ranks #1254 of 1841 (31th percentile; typical, unremarkable volume), and for J0897 the provider ranks #1129 of 10057 (89th percentile; typical, unremarkable volume) — together these positions signal meaningful activity in certain high‑cost agents but not consistent national leadership across all top products.

Office visit and ancillary service volumes show a substantial ongoing clinic load: 99214 accounts for 1K claims and $90.6K (6.3% of total Medicare revenue) and ranks #10652 of 479517 (98th percentile; notably above typical national volume), indicating above‑typical established‑patient E&M activity. High percentiles on routine lab and collection codes — 85025 1.5K claims $11.7K (95th percentile), 80053 1K claims $10.4K (95th percentile), and 36415 1.2K claims $9.7K (98th percentile) — reinforce that the practice performs frequent in‑office monitoring and specimen collection.

Imaging and supportive modalities are present but not dominant: 78815 $64.4K (4.5%) ranks #3192 of 6566 (51th percentile) and 78816 $20.7K (1.4%) ranks #1246 of 1983 (34th percentile), while radiopharmaceutical A9552 $7.9K (0.5%) ranks #1038 of 2411 (56th percentile). These entries suggest coordination with PET/CT imaging for staging or treatment planning rather than imaging as a primary revenue stream.

Provider tenure is long: the NPI was enumerated 2005-10-26 (~21 years ago), indicating an established presence in the market and likely sustained referral relationships. That longevity, combined with concentrated revenue from specific immunotherapies, suggests an experienced oncology practice focused on ongoing infusion care for established Medicare patients.

Operational implications: reliance on high-cost oncology biologics (J9299 and J9271) and a Medicare‑only billing footprint creates exposure to drug reimbursement shifts and utilization management policies centered on those agents. Given the top‑3 concentration (71.3%) and absence of Medicaid billing, payers and network managers should treat this provider as a Medicare‑focused oncology infusion site whose financial performance will track closely with reimbursement and utilization trends for the listed immunotherapies and supportive agents.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

72 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9299	Injection, nivolumab, 1 mg	18,280	$20	$438.7K
J9271	Injection, pembrolizumab, 1 mg	9,400	$40	$404.2K
J0897	Injection, denosumab, 1 mg	10,080	$20	$181.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,030	$90	$90.6K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	60	$1,090	$64.4K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	420	$80	$33.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	350	$90	$32.7K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	4,080	$10	$24.5K
J1439	Injection, ferric carboxymaltose, 1 mg	21,750	$1	$21.8K
78816	The patient is injected with a radiopharmaceutical tracer called FDG (fluoro–deoxyglucose, a radioactive substance containing glucose) about one hour before the imaging is scheduled to begin. The…	20	$1,090	$20.7K

Showing 1–10 of 72

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 72 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Wallace Peterson — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

72 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	21	30	14,400	$40	$671.6K
J9299	8	10	19,300	$20	$444.5K
J0897	12	200	2,040	$20	$62.7K
J2506	11	20	460	$90	$40.5K
78815	32	60	70	$380	$32.7K
J1439	18	30	25,880	$1	$26.4K
J9217	37	50	110	$130	$20.6K
J0885	5	10	3,180	$10	$19.2K
96413	19	80	60	$90	$18.2K
74177	133	160	170	$80	$15.3K

Showing 1–10 of 72

Related Providers

Other providers that share a Tax Identification Number (TIN) with Wallace Peterson, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Bryan Medical Center	NE	General Acute Care Hospital	$0	$56.9M
Alegent Creighton Clinic	NE	Family Medicine Physician	$0	$43.2M
The Physician Network	NE	Family Medicine Physician	$0	$3.1M
Eric Avery	NE	Hematology & Oncology Physician	$3.1M	$0
Kailash Mosalpuria	NE	Hematology & Oncology Physician	$2.9M	$0
Chi Health Clinic Specialty, LLC	NE	Hospitalist Physician	$0	$2.6M
Madhu Midathada	NE	Hematology & Oncology Physician	$2.3M	$0
Scott Mcham	NE	Hematology & Oncology Physician	$1.9M	$0
Sakeer Hussain	IA	Hematology & Oncology Physician	$1.9M	$0
Steven Dunder	NE	Hematology & Oncology Physician	$1.7M	$0

Nearby Providers

Other providers in the same ZIP code as Wallace Peterson, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Melvin Churchill	NE	Rheumatology Physician	$4.8M	$0
Lincoln Radiology Group PC	NE	Diagnostic Radiology Physician	$0	$4.5M
Elite Professionals Home Care LLC	NE	Home Health Agency	$0	$4.2M
Rick Chatwell	NE	Rheumatology Physician	$3.5M	$0
Lincoln Pediatric Group LLC	NE	Pediatrics Physician	$0	$2.3M
Nebraska House Call Physicians, P.C.	NE	Internal Medicine Physician	$0	$1.7M
Urology Surgical Center LLC	NE	Ambulatory Surgical Clinic/Center	$1.4M	$190.5K
Irfan Vaziri	NE	Medical Oncology Physician	$1.4M	$0
Stacey Knox	NE	Hematology & Oncology Physician	$1.4M	$0
David Brockman	NE	Orthodontics and Dentofacial Orthopedics Dentistry	$0	$1.2M

Wallace Peterson — Billing Profile & Reimbursement Data

Sign up for Wallace Peterson — Billing Profile & Reimbursement Data policy alerts

Wallace Peterson — Billing Profile & Reimbursement Data

Sign up for Wallace Peterson — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References